· Test offers early blood-based detection and discrimination of six high-utility, frequently occuring cancer types: three sarcomas, two lymphomas, and malignant melanoma, each with balanced accuracy ...
Oxford, UK - 4 June 2024 - Oxford BioDynamics Plc (AIM: OBD, the "Company"), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform, announces ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback